LKFT

33.3100.24%
GS

Glenn Schulman

Head of Investor Relations

Dr. Glenn Schulman, PharmD, MPH, is Head of Investor Relations of Lakefront Biotherapeutics NV (formerly known as Galapagos NV). He served as Vice President, Head of Investor Relations & Corporate Communications at IN8bio, Inc. since April 2024 until 2024. He served as Senior Vice President of Investor Relations at ProKidney Corp. since August 2022. He served as Vice President of Investor Relations & Corporate Communications at X4 Pharmaceuticals, Inc. Dr. Schulman served as Senior Vice President of Corporate Communications at Aurinia Pharmaceuticals Inc. since July 18, 2019 and serves as its Investor Relations. He served as Consultant at Aurinia Pharmaceuticals Inc. He served as Executive Director of Investor Relations at Achillion Pharmaceuticals, Inc. He served as Director of Investor Relations at CuraGen Corporation. He was Senior Vice President, Investor Relations and Corporate Communications at Aurinia Pharmaceuticals. Prior to joining Aurinia, he led Corporate Communications and Investor Relations at Achillion Pharmaceuticals, Inc. Prior to Achillion, he held positions of increasing responsibility at CuraGen Corp. where he was ultimately responsible for all aspects of corporate and medical communications, investor and public relations. Dr. Schulman received his BS Pharmacy from Philadelphia College of Pharmacy, Doctor of Pharmacy Degree from Rutgers, Ernest Mario School of Pharmacy and completed a Post-Doctoral Fellowship at Memorial Sloan-Kettering Cancer Center. Dr. Schulman received his MPH, Health Management, from Yale University.

Positions